Indian pharmaceutical firm Intas acquires Actavis from global generics major Teva
India’s Intas Pharmaceuticals has acquired leading UK and Ireland generics business Actavis from global generics player Teva in an all-cash deal valuing the enterprise at £600 million ($764 million), the Business...To view the full article, register now.
Already a subscriber? Click here to view full article